Furthermore, the ability of the assay to perform mutational analysis of hundreds of cancer genes at once provides insight into additional oncogenic drivers, mutational co-occurrence patterns, tumor heterogeneity, and the potential to identify homologous recombination and DNA repair genes beyond BRCA1 and BRCA2 that may be involved in response to olaparib and other PARP inhibitors. This evidence concerns the gene BRCA2 and cancer.